About THAOS

The Transthyretin Amyloidosis Outcomes Survey (THAOS), established in 2007, is a longitudinal, observational survey open to all clinicians following individuals who are gene carriers for, or who treat patients with, transthyretin amyloidosis.

Transthyretin amyloidosis is a systemic disorder. Disease progression is relentless, with severe debilitation and an average life expectancy of 10 years after symptom onset in the predominantly polyneuropathy phenotype,1‒4 and approximately 5 years in the predominantly cardiomyopathy phenotype.1

The clinical course of the many genetic mutations underlying transthyretin amyloidosis is scarcely known, and for the more common mutations the clinical presentation is complex.1

Data from these subjects participating in the THAOS registry are analyzed on a regular basis and provide a valuable insight into this rare disease and its treatment.

To date, over 4000 subjects are being enrolled in THAOS from 55 active sites in 17 countries worldwide.